How does TSHA's Q4 2024 EPS compare to industry peers?

Taysha Gene (TSHA) showed a significant increase in its Q4 2024 EPS, with a value of $0.92 compared to $0.15 in the previous quarter, a 517% rise. While this is a substantial improvement, it is important to note that TSHA's EPS was still lower than that of some industry peers. For instance, Biogen (BIIB) reported an EPS of $4 in Q4 2024, compared to $2.7 in the previous quarter, a 48% increase. Similarly, Abbvie (ABBV) showed an EPS of $0.88 in Q4 2024, up from $0.77 in the previous quarter, a 15% increase. Pepsico (PEP) demonstrated a more moderate increase in its EPS, with a value of $2.23 in Q4 2024, up from $2.13 in the previous quarter, a 5% rise. Regeneron (REGN) and Vertex Pharmaceuticals (VRTX) also had higher EPS values in Q4 2024, with $8.75 and $12.52 respectively. Overall, while TSHA's EPS showed a strong improvement, it is still lower than that of some industry peers.

|code|Ticker|Name|Date|Diluted EPS|market_code|
|---|---|---|---|---|---|
|IONS|IONS.O|Ionis Pharmaceuticals|2024 Q1|-0.98|185|
|TSHA|TSHA.O|Taysha Gene|2024 Q1|-0.1|185|
|BIIB|BIIB.O|Biogen|2024 Q1|2.7|185|
|ABBV|ABBV.N|Abbvie|2024 Q1|0.77|169|
|PEP|PEP.O|Pepsico|2024 Q1|1.48|185|
|IONS|IONS.O|Ionis Pharmaceuticals|2024 Q2|-0.45|185|
|TSHA|TSHA.O|Taysha Gene|2024 Q2|-0.09|185|
|BIIB|BIIB.O|Biogen|2024 Q2|4|185|
|ABBV|ABBV.N|Abbvie|2024 Q2|0.77|169|
|PEP|PEP.O|Pepsico|2024 Q2|2.23|185|